Thoracic radiotherapy for extensive-stage small-cell lung cancer: What is the optimal dose and timing

Basit Öğe Kaydı
dc.contributor.authorYavas, Guler.
dc.contributor.authorYavas, Cagdas.
dc.date.accessioned2020-03-26T20:19:37Z
dc.date.available2020-03-26T20:19:37Z
dc.date.issued2019
dc.departmentSelçuk Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.description.abstractSmall-cell lung cancer (SCLC) is a neuroendocrine tumor that represents about 12-20% of all lung cancers. Most of the SCLC patients present with extensive-stage (ES) disease. Primary therapy for ES-SCLC is 4-6 cycles of platinum-based chemotherapy (CT) followed by prophylactic cranial irradiation (PCI) in selected cases. Although the response rate to CT is approximately 60-70%, median survival times are very limited. The main problem of ES-SCLC patients after CT is intra-thoracic tumor recurrence since 75% of the patients had persisting intra-thoracic disease after CT, and approximately 90% of the patients had intra-thoracic progressive disease within the first year after diagnosis. Such high rate of intra-thoracic disease progression explains the need of local treatment in selected patients. There are three randomized studies and two meta-analyses evaluating the role of thoracic radiotherapy (TRT) in patients with ES-SCLC who responded to CT. Two of the randomized trials and one of the meta-analyses showed survival benefit of TRT. According to the results of relevant studies, the patients who responded to CT and have intra-thoracic residual disease after CT, who had limited metastatic sites (<= 2), and who have good performance status and limited weight loss have more benefit from TRT. We need novel studies evaluating the optimal dose fractionation schedules, optimal timing of RT, impact of time interval between RT and CT, immunotherapy and RT combinations, and number of CT cycles.en_US
dc.identifier.citationYavas, G., Yavas, C. (2019). Thoracic Radiotherapy for Extensive-Stage Small-Cell Lung Cancer: What is the Optimal Dose and Timing?. Journal of Radiation Oncology, 8(3), 251-258.
dc.identifier.doi10.1007/s13566-019-00406-xen_US
dc.identifier.endpage258en_US
dc.identifier.issn1948-7894en_US
dc.identifier.issn1948-7908en_US
dc.identifier.issue3en_US
dc.identifier.pmid#YOKen_US
dc.identifier.startpage251en_US
dc.identifier.urihttps://dx.doi.org/10.1007/s13566-019-00406-x
dc.identifier.urihttps://hdl.handle.net/20.500.12395/38340
dc.identifier.volume8en_US
dc.identifier.wosWOS:000494069300001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.institutionauthorYavas, Guler.
dc.institutionauthorYavas, Cagdas.
dc.language.isoenen_US
dc.publisherSPRINGER HEIDELBERGen_US
dc.relation.ispartofJOURNAL OF RADIATION ONCOLOGYen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectSmall-cell lung canceren_US
dc.subjectExtensive stageen_US
dc.subjectThoracic radiotherapyen_US
dc.subjectRadiation doseen_US
dc.subjectSurvivalen_US
dc.titleThoracic radiotherapy for extensive-stage small-cell lung cancer: What is the optimal dose and timingen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
Ä°sim:
Guler YAVAS.pdf
Boyut:
346.53 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Full Text Access
Ä°ndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Radyasyon Onkolojisi/Makale Koleksiyonu